Related Experiment Videos
[Clinical and pharmacokinetic studies of rokitamycin in children]
H Meguro1, O Arimasu, H Shiraishi
1Department of Pediatrics, School of Medicine, Teikyo University.
Insights
Rokitamycin dry syrup (RKM) showed effectiveness against certain pediatric infections like mycoplasmal pneumonia but was insufficient for others. While RKM achieved higher blood concentrations, individual variations and mild diarrhea were noted side effects.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Clinical microbiology
Context:
- Evaluation of a novel macrolide antibiotic, Rokitamycin dry syrup (RKM).
- Study conducted on 19 pediatric patients.
- Assessment of safety, efficacy, and pharmacokinetics.
Purpose:
- To determine the clinical utility of RKM in treating various pediatric infections.
- To analyze the pharmacokinetic profile of RKM in children.
- To identify potential side effects and safety concerns.
Summary:
- RKM demonstrated efficacy in treating mycoplasmal pneumonia, Chlamydia trachomatis pneumonitis, and Campylobacter gastroenteritis.
- Insufficient efficacy was observed for streptococcal pharyngitis and Haemophilus influenzae pneumonia.
- Pharmacokinetic data suggested higher blood concentrations compared to older macrolides, with significant individual variability.
- Diarrhea was the sole side effect, occurring in 2 of 17 evaluable cases.
Impact:
- Rokitamycin dry syrup may be a valuable therapeutic option for specific pediatric infectious diseases.
- Further research may be warranted to optimize RKM dosing and expand its clinical applications.
- Highlights the importance of individualized pharmacokinetic assessments in pediatric antibiotic therapy.
Abstract:
Rokitamycin dry syrup (RKM), a new macrolide antibiotic preparation, was evaluated for its safety, efficacy and pharmacokinetics in 19 children. RKM was effective in mycoplasmal pneumonia, Chlamydia trachomatis pneumonitis and Campylobacter gastroenteritis. Efficacies of RKM in streptococcal pharyngitis and Haemophilus influenzae pneumonia, however, were insufficient. Pharmacokinetic observations seemed to indicate that RKM achieved higher blood concentrations than older macrolides, but a large individual variation was observed. Diarrhea which was the only type of side effect observed in our cases, was encountered in 2 of 17 evaluable cases. From these data, RKM seems to have a place in the treatment of pediatric infectious diseases.